SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi is trending as investors anticipate potential catalysts including strong earnings, a possible rate cut, and the addition of crypto trading to the platform. Community members are also speculating about potential S&P 500 inclusion in the near future. Some traders express concerns about short-term volatility and potential pullbacks, while long-term bulls remain confident in SoFi's growth prospects and innovative approach to digital banking.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a temporary halt in Phase 3 trials for its gene therapy nex-z following a patient hospitalization with liver toxicity. The community is discussing whether this is a buying opportunity, comparing it to other biotech setbacks, and awaiting the company's conference call for further details. Broader context includes safety-related pauses being common in gene therapy trials, and the potential impact on the competitive landscape.

Richtech Robotics, Inc. engages in the development of robotic technologies. The firm designs, manufactures, and sells robots to restaurants, hotels, senior living centers, casinos, factories, and movie theaters. Its robots perform a variety of services including restaurant running and bussing, hotel room service delivery, floor scrubbing and vacuuming, and beverage and food preparation. The company was founded by Zhen Wu Huang and Zhen Qiang Huang on July 19, 2016 and is headquartered in Las Vegas, NV.

Richtech Robotics Inc. - Ordinary Shares - Class B

Richtech Robotics Inc.

Richtech Robotics ($RR) is trending as excitement builds for its participation in the NVIDIA GTC conference, where the company is expected to reveal a new humanoid robot. The community is speculating about potential partnerships and the robot's capabilities, while also weighing the implications of a recent share authorization increase. Some traders are wary of potential short attacks or a "sell the news" event, while others remain bullish, anticipating a significant move for the robotics company.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending amid discussions about its valuation, potential turnaround, and founder Chip Wilson's renewed involvement. Community members are actively debating whether the stock is poised for a rebound or further decline, with some pointing to strong international growth and others citing concerns over tariffs and competition. The stock's price action around the $180 level is also a key focus of conversation.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community anticipates a breakout, fueled by the renewed 'WAGMI' (We're All Gonna Make It) sentiment. Discussions revolve around its potential to outperform, with some eyeing key resistance levels and others highlighting the strength of its meme ecosystem. Despite some concerns about potential pullbacks, the overall mood is optimistic, with community members expressing strong conviction.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

CLIK is trending due to renewed trading momentum and discussions around its low float. Community members are actively debating potential price targets and short squeeze opportunities, with some comparing it to other Chinese stocks with similar patterns. The stock's high insider ownership and recent revenue growth are also fueling speculation about its future potential.

Unusual Machines, Inc. is a development stage technology company, which engages in the provision of drone solutions with a focus on first-person view (FPV) technology. It offers products to entertainment, recreation, and competitive racing industries. The company was founded on July 11, 2019, and is headquartered in Orlando, FL.

Unusual Machines Inc

Unusual Machines, Inc.

UMAC is trending due to growing interest in drone stocks and a recent contract secured by the company. Community members are discussing the company's potential in the drone component supply chain, particularly given its U.S.-based manufacturing and ties to Donald Trump Jr. The broader context involves increasing government spending and policy support for domestic drone production.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as the White House reposted a meme from the company, sparking excitement among retail investors and talk of a potential short squeeze. The community is drawing comparisons to past meme stock rallies and analyzing the potential for significant price movement. Discussions also include speculation about the involvement of key figures and the overall market dynamics influencing the stock.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRSP is trending due to concerns sparked by Intellia's (NTLA) halted trials over liver safety issues, dragging down related gene-editing stocks; the community is debating whether this presents a buying opportunity or reflects broader sector risks. Despite the setback, some investors remain optimistic, pointing to CRSP's own pipeline, upcoming presentations, and strong financial position, while others are wary of potential dilution from a recent share offering.

Keurig Dr Pepper, Inc. engages in the manufacture, marketing, distribution, and sales of non-alcoholic beverages. It operates through the following segments: U.S. Refreshment Beverages, U.S. Coffee, and International. The U.S. Refreshment Beverages segment manufactures and distributes beverage concentrates, syrups, and finished beverages including the brands Dr Pepper, Canada Dry, Mott’s, Snapple, A&W, 7UP, Sunkist soda, Squirt, Hawaiian Punch, Core Hydration, Bai, C4 Energy, Clamato, Evian, Yoo-Hoo, Big Red, and Vita Coco. The U.S. Coffee segment involves single serve brewers, specialty, hot and iced varieties, and ready-to-drink beverages. The International segment includes sales in Canada, Mexico, and other markets. The company was founded in 2018 and is headquartered in Burlington, MA.

Keurig Dr Pepper Inc

KDP is trending amid news of a strategic $7 billion financing plan for a JDE Peets deal, sparking discussions about the company's debt levels and future growth. Community members are actively debating the potential split of the beverage and coffee businesses and its impact on stock value, with some expressing optimism for a recovery to $30 and beyond following earnings.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Praxis Precision Medicines (PRAX) Surges 183.7%: Is This an Indication of Further Gains?

Praxis Precision Medicines (PRAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Praxis Precision Medicines rose 5% in premarket trading on Friday&nbsp;as bullish calls from Wall Street that were based on strong late-stage trial results for its experimental essential tremor therapy outweighed pressure from a share offering.&nbsp;&nbsp;The stock surged 184% to $162.71 on Thursday and gained another 5.3% in after-hours trading.Analysts Boost Targets Following Essential Tremor DataJefferies raised its price target on Praxis to $300 from $65, saying the firm expects “significant stock upside” following the Phase 3 ESSENTIAL3 program success in essential tremor, an indication it values as a $2.5 billion-plus opportunity. The brokerage estimated 70% odds of approval and expects Praxis to file for U.S. regulatory clearance in early 2026.Guggenheim raised its target to $350 from $155, citing the “robustness” of the data and the significant unmet need in the disorder, estimating the opportunity at over $2 billion in the U.S. and assuming an 80% probability of approval.JonesResearch made the most bullish call, hiking its price target to $441 from $83, projecting ulixacaltamide could reach blockbuster status by 2028 with potential 2032 sales of $12.2 billion, assuming U.S. approval in the first quarter of 2027.H.C. Wainwright more than doubled its target to $232 from $115, saying the trial’s positive topline data was “a big surprise” given earlier futility concerns. The firm now sees 85% odds of approval and peak sales of $3.3 billion by 2035.Oppenheimer raised its target to $250 from $115, calling the results a “double-win” and highlighting ulixacaltamide’s clean safety profile and clear regulatory path. TD Cowen followed suit, increasing its target to $251 from $61, while Truist and Baird raised theirs to $360 and $275, respectively.Ulixacaltamide’s Phase 3 Success&nbsp;Praxis said patients who received ulixacaltamide in its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-praxis-precision-medicines-stock-surge-pre-market-today/ch6pbpbR3nE">late-stage study</a> experienced a 4.3-point mean increase in Modified Activities of Daily Living 11 (mADL11) score, which is a measure of functional independence. The benefit was sustained across the entire 12-week treatment period, suggesting that patients derive a consistent benefit throughout the trial.&nbsp;Praxis said it expects to file for U.S. regulatory approval by early 2026. The drug was generally well-tolerated with no deaths or serious side effects reported in the study, though more patients in the ulixacaltamide arm discontinued the study drug due to mild or moderate reactions.Essential tremor is a neurological condition that affects about seven million people in the U.S. and has limited treatment options today. Analysts believe ulixacaltamide could become one of the first major new therapies to address this gap if approved.Capital Raise To Fund Launch PreparationsPraxis announced the pricing of a $525 million public offering late Thursday, issuing shares at $157 each and pre-funded warrants at $156.9999. The proceeds will strengthen its balance sheet ahead of regulatory filings and potential commercialization.TD Cowen, Piper Sandler, Guggenheim Securities, and Truist Securities are acting as joint book-running managers for the offering, which is expected to close on October 20, 2025.Stocktwits Traders Weigh Profit-Taking vs. Optimism After RallyOn Stocktwits, retail sentiment for Praxis was ‘extremely bullish’ amid ‘extremely high’ message volume.One retail trader said that Praxis’s $157 per-share offering looked steep, saying the company was “taking advantage of the price run” but acknowledging the move made sense given Thursday’s rally.<stembedurl>https://stocktwits.com/Ryan4vp/message/632690328</stembedurl>Another user noted that with “all the analyst upgrades,” the stock might hold up for a while despite the fundraising news.<stembedurl>https://stocktwits.com/eltrain84/message/632685557</stembedurl><a href="https://stocktwits.com/symbol/PRAX">Praxis’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Praxis’ stock (PRAX) has more than doubled so far in 2025. (Photo credit: Getty Images)

 Praxis Precision Stock Extends Rally Premarket As Wall Street Turns Hyper-Bullish After Essential Tremor Trial Win

Wall Street boosted the stock’s price targets after the company’s late-stage trial for its essential tremor drug, ulixacaltamide, delivered strong efficacy and safety data.

Equity

Futures Rise As Strong TSMC Results Reboot AI Optimism

Futures Rise As Strong TSMC Results Reboot AI Optimism Stock futures rose as an olive branch from Treasury Secretary Bessent calmed trade-war fears, while a guidance hike from chipmaker TSMC (which...

Praxis Precision Medicines, Inc. (PRAX) announced on Thursday that patients with essential tremor treated with Ulixacaltamide in a late-stage study showed improvement in functional independence.A 4.3 point mean improvement in the Modified Activities of Daily Living 11 (mADL11) score was observed at week 8 in the trial, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-1">said</a>. The score is used to assess a person's functional independence and evaluate a person’s ability to do day-to-day activities. Furthermore, the effect was sustained from week 2 throughout the 12-week dosing period, it added.Essential Tremor is the most common movement disorder, affecting roughly seven million people in the U.S. alone, according to Praxis. It is characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body locations such as the head, vocal cords, or legs.Praxis now plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026. Shares of the company rallied 76% in the pre-market session at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/PRAX">PRAX stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory, while message volume increased from ‘low’ to ‘extremely high’ levels.The company said that Ulixacaltamide was generally well-tolerated over 12 weeks of treatment, and no deaths or drug-related serious adverse events were recorded. However, discontinuations in the study were 35.6% in patients who received Ulixacaltamide as compared to 5.6% in patients who received placebo, and most discontinuations were primarily due to treatment-emergent adverse events, it said.The company also conducted another late-stage trial where patients showed superior maintenance of effect while on Ulixacaltamide versus placebo after blinded exposure for 8 weeks with Ulixacaltamide.PRAX stock is down by 25% this year and by about 23% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/alibaba-executive-reportedly-says-company-beginning-to-see-return-on-ai-investment-in-e-commerce/ch6pRcFR3nf">Alibaba Executive Reportedly Says Company Beginning To See Return On AI Investment In E-Commerce: Forecasts ‘Very Significant’ Positive Impact</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Why Did Praxis Precision Medicines Stock Surge 69% In Pre-Market Today?

The company plans to submit an application to the U.S. Food and Drug Administration for approval of Ulixacaltamide in essential tremor by early 2026.

Deutsche Bank initiates coverage of biopharma stocks, sees 'modest recovery'

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced Biogen (Nasdaq: BIIB), Praxis Precision Medicines (Nasdaq: PRAX) and Stoke Therapeutics...

Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug

Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction...

Praxis Precision Medicines' Promising EMBOLD Study Outcomes

The latest update is out from Praxis Precision Medicines (PRAX). Praxis Precision Medicines, Inc. has reported promising results from its EMBOLD st...

These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results

Latest Ratings for PRAX
 DateFirmActionFromTo Dec 2021HC Wainwright & Co.Initiates Coverage OnBuy Aug 2021B of A SecuritiesInitiates Coverage OnBuy Apr 2021William BlairInitiates Coverage...

Analysts' Top Healthcare Picks: Immunocore Holdings (IMCR), Praxis Precision Medicines (PRAX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunocore Holdings (IMCR Research Report) and Praxis Precision Medicines...

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	$173.97
Prev Close	$178.01
Open	$180.93
Dividend Yield	0.00%
50-Day Moving Average	$66.12
Beta	0.44
Avg. Volume	497,013.71
PE Ratio	-14.16

52-Week High	$205.89
52-Week Low	$26.70
Market Capitalization	$4.21B
EPS (Annual)	-$10.21
Price to Book	9.06
Revenue Per Employee	$73,732.76
Enterprise Value/EBITDA	N/A

PRAX
Praxis Precision Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest PRAX News

PRAXPraxis Precision Medicines Inc